Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Wednesday 10 October, 2001

Xenova Group PLC

Research Update

Xenova Group PLC
10 October 2001

Xenova Group plc

Results of TA-HSV Phase II Trial for the Treatment of Genital Herpes



Slough, UK 10th October, 2001 - Xenova Group plc (Nasdaq NM: XNVA; London
Stock Exchange: XEN), today announced results from the Phase II clinical
efficacy trial conducted in collaboration with its partner, GlaxoSmithKline
(GSK), with TA-HSV (a therapeutic vaccine designed for the treatment of
genital herpes). Analysis has shown that the trial has not met its clinical
endpoints.



The multi-centre, placebo controlled study was conducted amongst 483 HSV-2
seropositive patients with symptomatic recurrent genital herpes.  No
significant difference was seen between the treatment arm and the control
group with respect to time to first recurrence, the total number of
recurrences or other clinical outcomes assessed during the course of the
study. Further development by GSK of the therapeutic vaccine TA-HSV is not
planned and the TA-HSV development agreement between the two companies will be
terminated effective January 2002.



Xenova to continue development of prophylactic herpes vaccine, DISC-PRO



Xenova will continue to develop DISC-PRO, a prophylactic vaccine designed to
prevent genital and oro-labial herpes. Xenova holds all rights to DISC-PRO.



Phase I results using DISC-PRO among seronegative subjects (people who have
not been previously exposed to the herpes virus) have demonstrated excellent
safety and immunogenicity responses.  The immunogenicity responses have
reached levels which are believed to be appropriate for the prevention of both
genital and oro-labial herpes.  In addition, preclinical  studies have shown
that vaccination using DISC-PRO is capable of preventing herpes disease with
greater than 90% efficacy following viral challenge. The work conducted to
date for the development of TA-HSV, especially that relating to manufacturing
and scale-up, provides significant support for the further development of
DISC-PRO.



The company believes, on the basis of available preclinical and clinical trial
results, that prevention of genital and oro-labial herpes by vaccination
remains an achievable and highly desirable goal and intends to seek a
corporate partner in due course to support late stage clinical trials.



                                    -end-



Contacts



UK
Xenova Group plc                                  Financial Dynamics
Tel: +44 (0) 1753 706600                          Tel: +44 (0) 207 831 3113
David Oxlade: Chief Executive Officer             David Yates/Fiona Noblet
Daniel Abrams: Finance Director
Hilary Reid Evans: Corporate Communications



US

BMC Communications
Tel: 001 212 477 9007
Brad Miles (Ext 17)/Lauren Tortorete (Ext 20)


Notes to Editors


Xenova's product pipeline focuses principally on the therapeutic areas of
cancer, infectious, autoimmune and cardiovascular diseases.  The Group has a
well-established track record in the identification, development and
partnering of innovative products and technologies.  Xenova has partnerships
with a number of major pharmaceutical companies including Lilly, Pfizer,
Celltech and QLT Inc.


For further information about Xenova and its products please visit the Xenova
website at www.xenova.co.uk.


Safe Harbor Statement under the US Private Securities Litigation Reform Act of
1995: Some or all of the statements in this document that relate to future
plans, expectations, events, performances and the like are forward-looking
statements, as defined in the US Private Securities Litigation Reform Act of
1995.  Actual results of events could differ materially from those described
in the forward-looking statements due to a variety of factors, including those
set forth in the Company's filings with the US Securities and Exchange
Commission.